J.ophthalmol.(Ukraine).2019;2:50-54.

http://doi.org/10.31288/oftalmolzh201925054

Received: 14 January 2019; Published-online: 24 April 2019


On selenium deficiency in Graves’ disease patients with autoimmune ophthalmopathy 

Yu.V. Buldygina, Cand Sc (Med); G.M. Terekhova, Cand Sc (Med); T.V. Fed’ko, Endocrinologist; V.M. Klochkova, Research Fellow; L.S. Strafun, Junior Research Fellow; I. I. Savosko, Endocrinologist; Z.G. Lysova, Endocrinologist

Komisarenko Institute for Endocrinology and Metabolism of the NAMS of Ukraine; Kyiv (Ukraine)

E-mail: Yuliya.buldygina@icloud.com

TO CITE THIS ARTICLE: Buldygina YuV, Terekhova GM, Fed’ko TV, Klochkova VM, Strafun LS, Savosko II, Lysova Z.G. On selenium deficiency in Graves’ disease patients with autoimmune ophthalmopathy. J.ophthalmol.(Ukraine).2019;2:50-4. http://doi.org/10.31288/oftalmolzh201925054


Background: The role of selenium (Se) deficiency in the development of thyroid associated ophthalmopathy has been actively debated in the literature. The question is still debated in Ukraine due to the absence of data both on selenium deficiency in this country and blood selenium levels in Graves’ disease patients with autoimmune ophthalmopathology (AO).

Purpose: To investigate blood selenium levels in Graves’ disease patients with AO.

Materials and Methods: Fifty-seven Graves’ disease patients were included in the study. Of these, 44 had AO. Clinical severity of AO was classified using the NOSPECS. Of the 44 patients with AO, 16, 19 and 9 patients had class 2b, class 3a or 3b, and class 4a, respectively. All patients were euthyroids receiving antithyroid therapy (mean TSH level, 1.36 ± 0.4 mIU/L; reference TSH range, 0.4 mIU/L to 4.0 mIU/L). A Hitachi MPF-2A fluorescence spectrophotometer was used to determine blood selenium levels. A blood selenium level between 75 and 120 μg/l was considered normal, between 50 and 75 μg/l was moderate Se deficiency, and <200 μg/l considered severe Se deficiency. 

Results: Of the 57 patients of both groups, 31 (54%) were found to be severely selenium deficient. The mean blood selenium level in Graves’ disease patients with AO was 60.07±7.61 μg/l, i.e., substantially lower than the normal range. In addition, 34% of these patients had a normal blood selenium level, whereas 16% and 50%, moderate and severe Se deficiency, respectively. The mean blood selenium level in Graves’ disease patients without AO was 34.4±10.2 μg/l, i.e., also substantially lower than the normal range. In addition, 31% of these patients had a normal blood selenium level, whereas 69%, severe Se deficiency.

Conclusion: First, irrespective of the presence or absence of AO, 54% of Graves’ disease patients were found to exhibit severe selenium deficiency. Second, the mean blood selenium level in Graves’ disease patients with AO was 60.07 ± 7.61 μg/l, and 50% of them exhibited severe selenium deficiency. In addition, the mean blood selenium level in patients with Graves’ disease only was 34.4 ± 10.2 μg/l, and 69% of them exhibited severe selenium deficiency. There was, however, no significant difference in blood selenium level between groups (Р > 0.05). Therefore, it may be assumed that selenium deficiency is not a factor affecting the development of AO in Graves’ disease. Finally, given that fact that 34% of Graves’ disease patients with AO exhibited no selenium deficiency, such patients should not be prescribed selenium agents without first checking their blood selenium levels.

Keywords: Graves’ disease, autoimmune ophthalmopathy, selenium

References

1.Przybylik-Mazurek E, Zagrodzki P, Kuźniarz-Rymarz S, Hubalewska-Dydejczyk A. Thyroid disorders-assessments of trace elements, clinical, and laboratory parameters. Biol Trace Elem Res. 2011 Jun;141(1-3):65-75. doi: 10.1007/s12011-010-8719-9. 

Crossref   PubMed  

2.Böck A, Forchhammer K, Heider J, Baron C. Selenoprotein synthesis: an expansion of the genetic code. Trends Biochem Sci. 1991 Dec;16(12):463-7.

Crossref   

3.Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol. 2011 Oct 18;8(3):160-71.

Crossref   PubMed

4.Hardy G, Hardy I, Manzanares W. Selenium supplementation in the critically ill. Nutr Clin Pract. 2012 Feb;27(1):21-33. 

Crossref    PubMed  

5.Rayman MP. Selenium and human health. Lancet. 2012 Mar 31;379(9822):1256-68. 

Crossref  

6.Schomburg L, Köhrle J. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res. 2008 Nov;52(11):1235-46. 

Crossref   PubMed

7.Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity and their role in human health. Antioxid Redox Signal. 2007 Jul;9(7):775-806.

Crossref   PubMed  

8.Köhrle J. Pathophysiological relevance of selenium. J Endocrinol Invest. 2013 Nov;36(10 Suppl):1-7.

9.Köhrle J, Jakob F, Contempré B, Dumont JE. Selenium, the thyroid, and the endocrine system. Endocr Rev. 2005 Dec;26(7):944–84.

Crossref   PubMed 

10.Gärtner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002 Apr;87(4):1687–91.

Crossref   PubMed  

11.Bhuyan AK, Sarma D, Saikia UK. Selenium and the thyroid: A close-knit connection. Indian J Endocrinol Metab. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S354-5. doi: 10.4103/2230-8210.104090.

12.Contempre B, Denef JF, Dumont JE, Many MC. Selenium deficiency aggravates the necrotizing effects of a high iodide dose in iodine deficient rats. Endocrinology. 1993 Apr;132(4):1866–8.

Crossref   PubMed   

13.Contempre B, Le-Moine O, Dumont JE, Denef JF, Many MC. Selenium deficiency and thyroid fibrosis. A key role for macrophages and transforming growth factor beta (TGF-beta). Mol Cell Endocrinol. 1996 Nov 29;124(1-2):7-15.

Crossref  

14.Rasmussen LB, Schomburg L, Köhrle J, Pedersen IB, Hollenbach B, Hög A, et al. Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol. 2011 Apr;164(4):585-90. 

Crossref   PubMed 

15.Triggiani V, Tafaro E, Giagulli VA, Sabbà C, Resta F, Licchelli B, Guastamacchia E. Role of iodine, selenium and other micronutrients in thyroid function and disorders. Endocr Metab Immune Disord Drug Targets. 2009;18:277–94.

Crossref   PubMed  

16.Doupis J, Stavrianos C, Saltiki K, Mantzou E, Mastrokostopoulos A, Philippou G, Alevizaki M. Thyroid volume, selenium levels and nutritional habits in a rural region in Albania. Hormones (Athens). 2009 Oct-Dec;8(4):296-302.

Crossref   PubMed   

17.Goncharova OA. [Selenium and the thyroid gland (literature review and own research data)]. Endokrynologiya. 2014;19(2):149–55. Ukrainian.

18.Corvilain B, van Sande J, Laurent E, Dumont JE. The H2O2-generating system modulates protein iodination and the activity of the pentose phosphate pathway in dog thyroid. Endocrinology. 1991 Feb;128(2):779-85.

Crossref    PubMed

19.Corvilain B, Laurent E, Lecomte M, Vansande J, Dumont JE. Role of the cyclic adenosine 3',5'-monophosphate and the phosphatidylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab. 1994 Jul;79(1):152-9.

Crossref    PubMed   

20.Girgis CM, Champion BL, Wall Jr. Current concepts in Graves' disease. Ther Adv Endocrinol Metab. 2011 Jun;2(3):135-44. 

Crossref   PubMed  

21.Ludgate M. Animal models of Graves' disease. Eur J Endocrinol. 2000 Jan;142(1):1-8.

Crossref   PubMed 

22.Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A. Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics. 2011 Dec; 12(8): 564–75. 

Crossref  PubMed   

23.Weetman AP. Graves' disease. N Engl J Med. 2000 Oct 26;343(17):1236–48.

Crossref   PubMed  

24.Taylor EW. Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Biol Trace Elem Res. 1995 Aug-Sep;49(2-3):85-95.

Crossref   PubMed  

25.Dhamasena A. Selenium supplementation in thyroid associated ophthalmopathy: an update. Int J Ophthalmol. 2014;7(2):365–75.

26.Rotondo Dottore G, Leo M, Casini G, Latrofa F, Cestari L, Sellari-Franceschini S, et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves’ Orbitopathy. Thyroid.  2017 Feb;27(2):271-278. 

Crossref  PubMed

27.Calissendorff J, Mikulski EH, Larsen EH, Möller M. A prospective investigation of Graves’ disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur Thyroid J. 2015 Jun;4(2):93–8. 

Crossref   PubMed  

28.Marcocci C, Bartalena L. Role of oxidative stress and selenium in Graves′ hyperthyroidism and orbitopathy. J Endocrinol Invest. 2013 Nov;36(10 Suppl):15–20.

29.Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9–26.

Crossref   PubMed  

30.Patterson P, Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: a workshop summary. Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):63–9.

31.Nuttall KL. Evaluating selenium poisoning. Ann Clin Lab Sci. 2006 Autumn;36(4):409–20.

32.Yang GQ, Wang SZ, Zhou RH, Sun SZ. Endemic selenium intoxication of humans in China. Am J Clin Nutr. 1983 May;37(5):872–81.

Crossref   PubMed 

33.Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973 Feb 9;179(4073):588–90.

Crossref   PubMed

34.Nazarenko II, Kislova IV, Guseynov TM. [Fluorometric determination of selenium by 2,3-diaminonaphthalene in biological materials]. Zhurnal analiticheskoi khimii. 1975;30(4):733–7. Russian.

The authors certify that they have no conflicts of interest in the subject matter or materials discussed in this manuscript.